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 ABSTRACT 
 
As one of the most useful tools to influence gut microbiota and body health, probiotics 
have been studied for over a century in the aspect of different diseases. Many animals 
experiments and randomized clinical trials(RCTs) are conducted to demonstrate their 
therapeutical effect. This systematic review discussed the effect of probiotics on three 
aspects of human health, obesity, type II diabetes(T2D) and digestive health. In this 
review, more than 20 randomized clinical trials are included and involved in a meta-
analysis using STATA 14.0 software. The outcome suggested that intervention of 
probiotics has beneficial effects on improving obesity and type II diabetes, but shows 
little effect on digestive health. However, due to the insufficient data collected in this 
meta-analysis, no definitive conclusion can be drawn and more RCTs are necessarily 
needed to investigate the effect of probiotics on human health in greater detail.  
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INTRODUCTION 
 
1.1 Probiotics 
According to the Food and Agriculture Organization (FAO)/World Health Organization (WHO), 
probiotics are defined as “live microorganisms which, when administered in adequate amounts, 
confer a health benefit on the host”. Guidelines are also launched regarding the evaluation of 
probiotics: for an adequate amount of health benefits, a dose of 5 billion colony forming units (cfu) 
has been recommended for at least 5 days (5•109CFU/day)[1]. To identify the benefits that 
probiotics can provide in human health, many researches have been conducted in recent decades.  
Early researches of probiotics were mostly concentrated on the nutritive functions as a form of 
food or dietary supplement[2]. Recently, the trend in research interest of probiotics has shifted to 
the therapeutic and medicinal purposes of probiotics, as a scientific evolution in gut microbiome 
and probiotics research has occurred[3]. There are a large number of experiments or clinical trials 
to figure out whether probiotics have effects on some certain kinds of diseases or metabolism 
abnormalities. A general conclusion is that probiotics can provide a wide range of benefits to 
human health, especially in the aspect of gut-related cases. 
The most studied and used probiotics in recent years are lactobacilli and Bifidobacterium. In 
addition to these two, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus rhamnosus, 
Lactobacillus Plantarum, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus sporogenes, 
Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium bifidum, Streptococcus 
thermophilus and Homeostatic Soil Organisms (HSO’s) are also commonly used in probiotics 
formulations[1]. A good probiotic needs to meet several criteria as follows: 1) it is capable of 
adhering to cells; 2) It can exclude or reduce adherence of pathogens; 3) It is able to persist, 
multiply and produce acids, hydrogen peroxide and bacteriocins that are antagonistic to pathogen 
growth; 4) It is safe, noninvasive, non-pathogenic and noncarcinogenic5) it can co-aggregate to 
produce a balanced microbiota[4]. 
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As a result of these researches, many kinds of probiotics products are developed. Yogurt and other 
dairy food rich in probiotics are well known to improve gut health, by strengthening the intestinal 
barrier function and stimulating the immune system[5]. “Probiotic dietary supplements” is regarded 
as the second largest probiotics market, following “probiotic food and beverage”[6]. Certain species 
of probiotics are made into tablets that can be taken by patients of certain kinds of diseases to help 
them improve body health. 
The aim of this review is to summarize three aspects that probiotics can be beneficial to human 
health, which are obesity, type II diabetes, and digestive health, by looking into related 
experiments and clinical researches. 
 
1.2 Obesity 
Nowadays, obesity has become a pandemic issue; more than 1.9 billion people are overweight. 
The most common cause of obesity is the imbalance between energy intake and energy expenditure. 
Genetic and environmental factors, including the fat mass- and obesity- associated gene FTO, low 
level of physical activity, high-fat diet and so on, are also important causes of obesity. Obese 
patients usually face greater risks of cardiovascular diseases, type 2 diabetes (T2D), dyslipidemia, 
hepatobiliary disease (non-alcoholic fatty liver disease, gallbladder dyskinesia, cholelithiasis) as 
well as lung, breast, uterine and ovarian cancer. In previous studies, it was mainly focused on 
environmental and dietary factor which could influence energy balance. With the understanding 
of obesity and human health developing, gut microbiota is being taken into consideration due to 
their effect on energy homeostasis, inflammation and so on, suggesting a new method against 
obesity. 
A large amount of scientific evidence indicates that the composition of gut microbiota is associated 
with obesity. In both animal and human studies, a higher abundance of Firmicutes, especially 
Lactobacilli is observed, with a lower proportion of the Bacteroidetes in obesity. Due to the fact 
that gut microbiota composition varies among everyone, the general situation is quite changeable 
in obese people[5].  
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N. Kobyliak et al., demonstrated that probiotics mixture and with nutraceutical have led to a 
significantly lower prevalence of obesity, reduction of insulin resistance, total and visceral adipose 
tissue (VAT) weight in the rat monosodium glutamate (MSG) obesity model. Supplementation of 
probiotics with omega-3 may have the most beneficial anti-obesity properties in their experiment[7]. 
However, not all the genera of probiotics are beneficial for losing weight. Taking the genera of 
Lactobacillus as an example, the effects of Lactobacillus vary according to the species: some 
species were linked to weight gain, while others were associated with weight loss[8]. Some clinical 
trials indicate that administration of Lactobacillus reuteri, Lactobacillus sakei, Lactobacillus 
acidophilus and L. casei was associated with weight gain in human, whereas consumption of 
Lactobacillus gasseri, Lactobacillus amylovorus and L. plantarum was associated with weight loss 
in obese humans, body fat loss in overweight people and in healthy individuals, respectively[5]. 
 
 
1.3 Type II Diabetes 
Type II diabetes mellitus is a metabolic disease which begins with increased insulin resistance (IR); 
patients of Type II diabetes mellitus(T2DM) cannot have their cells respond to insulin properly, 
and develop a high blood sugar level in the long term[9]. Family history of diabetes, overweight, 
and obesity, unhealthy diet, physical inactivity and smoking are the strongest risk factors for Type 
II Diabetes (T2D). It was estimated by WHO that 422 million adults aged over 18 years were living 
with diabetes in 2014 around the whole world (International diabetes federation. IDF diabetes atlas. 
7th edition Diabetes Atlas; 2015. http://www.diabetesatlas.org/.). This pandemic health issue has 
been studied for decades, from aspects including insulin and enzymes, and many therapeutical 
methods have been put into use. It caught people's attention that compared to non-diabetic patients, 
T2D patients have altered gut microbiota composition, mostly with a lower relative abundance of 
Firmicutes and a higher proportion of Bacteroidetes and Proteobacteria[7]. It is revealed by some 
animal studies that altered microbiota may contribute to the pathogenesis of insulin resistance and 
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thereby T2D by several mechanisms. Due to the alteration of gut microbiota given by probiotics, 
people started to study the relationship between probiotics and T2D. 
Some researches demonstrate that probiotics can help to manage the gut microbiota environment 
and increase the production of short chain fatty acids (SCFAs), like acetate and butyrate, which 
can decrease insulin resistance and promote pancreatic cells proliferation and development, by 
activating certain receptors. Both regulated gut microbiota and SCFAs can stimulate the secretion 
of GLP-1 and GLP-2, thus increasing insulin and adiponectin expression, and might contribute to 
the enhanced insulin sensitivity, as well as decreasing low-grade inflammation associated with 
T2D. 
 
1.4 Digestive Health  
Digestive health is a general concept including a wide range of diseases, such as ulcerative colitis 
(UC), Crohn's disease (CD), diarrhea, constipation and so on. Most digestive diseases are claimed 
to be associated with gastrointestinal tract. For example, UC and CD are two representative causes 
of chronic inflammation of gastrointestinal tract, leading to diarrhea, abdominal pain and other 
symptoms. Newborn babies have sterile gastrointestinal tract; bacteria ingested during the birth 
process will colonize the gastrointestinal tract. While babies grow, their intestinal flora becomes 
similar to their mothers' intestinal flora gradually[10]. Microbiota in intestines is responsible for 
functioning the immune system properly. Considering the fact that probiotics have great influence 
on gut microbiota and intestinal environment, researchers started to study whether probiotics can 
be used to treat digestive health problems, including constipation and diarrhea. 
For patients who go through radiotherapy at abdominal or pelvic cavity, radiation-induced enteritis 
is one of the most common complications. Seher Demirer, et al., have used lactobacillus bulgaricus 
strain isolated from yogurt along with radiation-therapy Wistar rats models, demonstrated that 
probiotics might have some beneficial effects against radiation-induced intestinal injury by 
accelerating healing ability and preventing bacterial translocation and diarrhea[11]. 
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Despite that several studies claim probiotics could be beneficial to gastrointestinal health, many 
research hold the point that the evidence is not enough to prove it. American College of 
Gastroenterology has conducted a meta-analysis of 53 randomized, controlled trials involving 
5545 patients with irritable bowel syndrome(IBS)[12]. The results of the analysis suggest that 
considered all together, probiotics were statistically superior to placebo with a relative risk of 
persistence of symptoms, but not significantly. After analyzing specific strands or combinations 
of probiotics, such as Lactobacillus Plantarum, Escherichia coli, Streptococcus faecium, and 
Bifidobacterium, researchers claimed that total adverse events were not statistically higher with 
probiotics comparing to placebos. The final statement of ACG was that probiotics may improve 
global symptoms, as well as bloating and flatulence in IBS patients, but the scientific evidence was 
not strong enough to confirm it. 
In a word, probiotics are a potential therapy for digestive health problems, due to its effect on gut 
microbiota composition and intestinal mucosa. While we have just started to dive into this research 
area, more studies and trials are needed to be conducted to provide deeper views. 
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METHODS AND MATERIALS 
 
2.1 Searching strategy and selection of RCTs for meta-analysis 
Databases used in this review includes PubMed, Web of Science, the Cornell Library, 
ClinicalTrials.gov. 
Literature was searched under such criteria[13]:  
-Types of study: randomized clinical trials. 
-Types of intervention: probiotics supplementation without restriction on dosage, strains, methods 
of administration. 
-Duration of study: longer than 3 weeks. 
-Types of control: placebo. 
 
2.2 Data collection process  
Based on literature search in the database, the following data were collected: 
-Study identification including author name and year of publication. 
-Study design information including country, duration of intervention, sample size and characters 
in each group, probiotics strains and dosage used in the intervention. 
-Primary outcomes and secondary outcomes including detailed data of related factors. 
Literature without sufficient data was excluded in meta-analysis. 
Studies with sufficient data were include in forest plots made via STATA 14.0 software. Factors 
collected were as following: 
-Obesity: Body Mass Index(BMI), waist circumference(WC), fat mass. 
-Type II diabetes: Homeostasis Model Assessment-Insulin Resistance(HOMA-IR), insulin, 
systolic blood pressure(SBP) and diastolic blood pressure(DBP). 
-Digestive health: stool consistency, frequency of defecation, abdominal pain, colonic transit 
time(CTT). 
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RESULTS 
 
3.1 Summary of Study 
Among literature identified, 8 RCTs about obesity, 6 RCTs about type II diabetes, and 7 RCTs 
about digestive health in total were included and the main design information was summarized in 
Table 1, 2, 3. 
 
3.2 Effect of probiotics on obesity 
7 RCTs in total have reported the Body Mass Index (BMI) in their results. Administration of 
probiotics has led to a significant decrease in BMI (-0.44, 95% CI: -0.67, -0.20) (Fig. 1). Waist 
circumference was also reported in 7 RCTs, which is proved to be decreased significantly after the 
intervention of probiotics (-1.57 cm, 95% CI: -2.20, -0.94) (Fig. 2). A decrease was noted in the 
effect of probiotics on body fat mass (-1.23, 95% CI: -2.75, 0.30), however, it is not significant 
(Fig. 3). 
 
Fig. 1. Forest plot of BMI that compares between probiotics intervention group and placebo group. 
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Fig. 2. Forest plot of waist circumference that compares between the probiotics intervention group 
and placebo group.  
 
Fig. 3. Forest plot of Fat Mass that compares between the probiotics intervention group and 
placebo group.  
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3.3 Effect of probiotics on T2D 
As one of the most important factor in T2D, HOMA-IR (Homeostasis Model Assessment-Insulin 
Resistance) showed a significant decrease (-1.25, 95%CI: -2.48, -0.23)  in probiotics intervention 
group overall in Fig. 4, despite that one study in 2017 held the opposite outcome. Blood insulin 
level was also greatly decreased by probiotics (-2.88, 95%CI: -5.68, -0.09) (Fig.5). However, 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) failed to show any significant 
change due to the intake of probiotics (Fig. 6 and Fig. 7). 
 
Fig. 4. Forest plot of HOMA-IR that compares between the probiotics intervention group and 
placebo group.  
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Fig. 5. Forest plot of insulin that compares between the probiotics intervention group and placebo 
group.  
 
Fig. 6. Forest plot of systolic blood pressure that compares between the probiotics intervention 
group and placebo group.  
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Fig. 7. Forest plot of diastolic blood pressure that compares between the probiotics intervention 
group and placebo group.  
 
3.4 Effect of probiotics on digestive health 
4 RCTs have reported stool consistency measured by the Bristol Stool Scale. After the 
administration of probiotics, stool consistency was significantly improved by 0.56 (95% CI: 0.06, 
1.03) (Fig. 8). Frequency of defecation was also improved overall by 0.32 (95% CI: -0.32, 0.96), 
but not significantly enough (Fig. 9). No great impact was detected in aspect of abdominal pain 
and bloating (-0.04, 95% CI: -0.19, 0.10; 0.59, 95% CI: -0.40, 1.58, respectively) (Fig. 10 and Fig. 
11). Colonic transit time (CTT) was decreased by probiotics by 2.49 (95% CI: -24.18, 19.21), but 
a great inconsistency was observed among these trials (Fig. 12). 
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Fig. 8. Forest plot of stool consistency that compares between the probiotics intervention group 
and placebo group. 
 
Fig. 9. Forest plot of the frequency of defecation that compares between the probiotics intervention 
group and placebo group.  
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Fig. 10. Forest plot of abdominal pain that compares between the probiotics intervention group 
and placebo group.  
 
Fig. 11. Forest plot of bloating that compares between the probiotics intervention group and 
placebo group.  
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Fig. 12. Forest plot of colonic transit time that compares between the probiotics intervention group 
and placebo group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Study(year)
Countr
y
Study design
and duration
Population,
sex and age(y) Strain of probiotcis Sample size (n) Probiotics dose
Control
group
Results(Intervention vs control after
supplementation)
Osterberg et al
2015[14]
the
United
States
Randomized,
double-blind
placebo-controlled
trial,
4 weeks
Healthy non-
obese people
(BMI <30)
Age: 18-30 y
Male: 100%
VSL#3® (Streptococcus thermophilus
DSM24731, L. acidophilus
DSM24735, L. delbrueckii ssp.
bulgaricusDSM24734, L. paracasei
DSM24733, L. plantarum DSM24730,
B. longum DSM24736, B. infantis
DSM24737, and B. breve DSM24732)
Total: 20
Placebo group (high-fat,
hypercaloric diet +
placebo): n=11
Intervention
group(high-fat,
hypercaloric diet +
probiotics intervention):
n=9
Two sachets of VSL#3
(450 billion bacteria per
sachet)/day
Placebo+
high-fat,
hypercaloric
diet
Intervention group: body mass  and fat mass
increased less comparing with placebo group but
no significant changes in insulin sensitivity or
in vitro skeletal muscle pyruvate and fat
oxidation was detected.
Jung et al
2015[15]
Korea
Double-blind,
placebo-
controlled,
randomized trial,
12 weeks
Nondiabetic
overweight
subjects
Male: 34
(35.79%)
Female: 61
(64.21%)
L. curvatus HY7601  plantarum
KY1032
Total: 95
Placebo group: n=46
Intervention group:
n=49
L. curvatus HY7601 at 2.5
× 109 cfu/day and L.
plantarum KY1032 at 2.5 ×
109 cfu/day
Placebo
Intervention group:  reduced body weight (−0.65
± 0.23 kg), body fat percentage (−0.57 ± 0.19%),
body fat mass (−616 ± 161 g) , and L1
subcutaneous fat area (−2.68 ± 1.31 cm2).
Higashikawa
et al (2016)[16] Japan
Randomized,
double-blind,
placebo-controlled
clinical trial,
12 weeks
Age: 20–70 y
 Male: 23 (37%)
Female: 39
(63%)
 LP28: plant-derived lactic acid
bacterium (Pediococcus pentosaceus)
Total: 62
Placebo group: n=20
Intervention group I
(living LP28): n=21
Intervention group II
(heat-killed LP28) :
n=21
10 11 CFU/day Placebo
Intervention group II (heat-killed LP28): reduced
BMI (0.45 kg/m2, 95% CI (0.04, 0.86), p=0.035),
body fat percentage (1.11%, (0.39, 1.82),
p=0.002), body fat mass (1.17 kg (0.43, 1.92),
p=0.004) and waist circumference (2.84 cm (0.74,
4.93), p=0.009).
Famouri et al
2017[17] Iran
Randomized,
triple-blind,
placebo-controlled
clinical trial,
12 weeks
Obese children
with
sonographic
NAFLD
Age: 20-18 y
Male: 32 (50%)
Female: 32
(50%)
Lactobacillus acidophilus ATCC
B3208, Bifidobacterium lactis DSMZ
32269, Bifidobacterium bifidum
ATCC SD6576, Lactobacillus
rhamnosus DSMZ 21690.
Total: 64
Placebo group: n=32
Intervention group:
n=32
Lactobacillus acidophilus
ATCC B3208, 3 × 109 cfu;
Bifidobacterium lactis
DSMZ 32269, 6 × 109 cfu;
Bifidobacterium bifidum
ATCC SD6576, 2 × 109
cfu; Lactobacillus
rhamnosus DSMZ 21690,
2 × 109 cfu
Placebo
Intervention group: decreased mean cholesterol,
low-density lipoprotein-C, and triglycerides as
well as waist circumference; no significant
change in weight, body mass index, and body
mass index z score was detected.
(Continued on next page)
Table 1 Summary of RCTs about effect of  probiotics on obesity.
Study(year)
Countr
y
Study design
and duration
Population,
sex and age(y) Strain of probiotcis Sample size (n) Probiotics dose
Control
group
Results(Intervention vs control after
supplementation)
Gomes et al
(2018)[18]
Brazil
 Randomized,
double-blind,
placebo-
controlled, two-
arm, parallel-group
study, 8 weeks
Women with
excess weight or
obesity
Age: 20-59 y
Lactoba- cillus acidophilus LA-14,
Lactobacillus casei LC-11,
Lactococcus lactis LL-23,
Bifidobacterium bifidum BB-06, and
Bifidobacterium lactis BL-4
(DaniscoVR®)
Total: 43
Placebo group (dietary
intervention): 22
Intervention
group(dietary +
probiotics intervention):
21
2 × 1010 CFU/day
Placebo+
dietary
intervention
Intervention group(dietary+probiotics
intervention): reduced waist circumference (
p=0.03), waist-height ratio (p=0.02), conicity
index (p=0.03), plasma polyunsaturated fatty
acids (p=0.04); increased activity of glutathione
peroxidase ( p < 0.01).
Mohammadi-
Sartang et al
2018[19]
Iran
Randomized
double-blinded
controlled trial, 10
weeks
Obese adults
Male: 34 (39.1%)
Female: 53
(60.9%)
Bifidobacterium lactis Bb- 12
Total: 87
Placebo group: 43
Intervention group: 44
2 × 107 cfu/g Placebo
Intervention group: reduced body fat mass
(p=0.023), body fat percentage (p=0.028), waist
circumference (p=0.002), HOMA-IR (p=0.025),
triglyceride concentration (p=0.003).
Sanchis et al
2018[20]
Spain
Randomized,
double-blind,
placebo-controlled
clinical trial, 13
weeks
Obese children
Age: 10-15 y
Male: 24 (50%)
Female: 24
(50%)
B. pseudocatenulatum CECT 7765
Total: 48
Placebo group: n=25
Intervention group:
n=23
1 × 109 ~ 1 × 1010 colony
forming units (CFU)
Placebo
Intervention group: reduced circulating high-
sensitive C-reactive protein (p=0.026) and
monocyte chemoattractant protein-1 (P=0.032);
increased  high-density lipoprotein cholesterol
(Pp=0.035) and omentin-1 (P=0.023)
Kim et al
(2018)[21] Korea
Randomized,
double-Blind,
placebo-controlled
trial, 12 weeks
Obese adults
Age: 20–75 y
Female: 63
(70%)
Male: 27 (30%)
Lactobacillus gasseri BNR17
Total: 90
Placebo group: 30
Intervention group I
(high dose): 30
Intervention group II
(low dose): 30
Intervention group I (high
dose): 1× 1010 CFU/day
Intervention group II (low
dose): 1× 109 CFU/day
Placebo
Intervention group I (high dose): Reduced waist
circumferences significantly (P=0.012);
decreased visceral adipose tissue (VAT) (-21.6
cm2, P = .012).
Intervention group II (low dose): Reduced waist
circumferences significantly (P=0.045).
Table 1 (continued)
Table 2 Summary of RCTs about effect of probiotics on T2D.
Study(year) Country Study design
and duration
Population, sex and age(y) Strain of probiotcis Sample size (n) Probiotics
dose
Control
group
Results(Intervention vs control after
supplementation)
Tonucci et al
2017[22]
Brazil
Randomized,
double-blind,
placebo-controlled
study,
6 weeks
Adults with BMI lower than 35 kg/m2
and type 2 diabetes diagnosed for at
least one year
Age: 35-60 y
Male: 26 (57.8%)
Female: 19 (42.2%)
S. thermophilus TA-40, L. acidophilus
La-5, lactis BB-12
Total: 45
Placebo group: n=22
Intervention group:
n=23
Depends on the
date Placebo
Intervention group: reduced
fructosamine levels (-9.91 mmol/L;
p=0.04), hemoglobin A1c (-0.67%;
p=0.06); HbA1c (-0.31 for control group
vs -0.65 for probiotic group; p=0.02),
total cholesterol (+0.55 for control group
vs -0.15 for probiotic group; p=0.04) and
LDL-cholesterol (+0.36 for control group
vs -0.20 for probiotic group, p=0.03).
Sabico et al
2017[23]
the United
Kingdom
Single-center,
double- blind,
randomized,
placebo-controlled
study,
3 months
Adult Saudis with newly diagnosed
T2DM
Age: 30–60 y
Male: 40 (51.3%)
Female: 38 (48.7%)
Sachets with 2 g freeze-dried powder of
the probiotic mixture
®Ecologic®Barrier
(Winclove9probiotics, the
Netherlands).
Ecologic Barrier (2.5 × 109 cfu/g)
contains the following bacterial
strains: Bifidobacterium bifidum W23,
Bifi- dobacterium lactis W52,
Lactobacillus acidophilus W37,
Lactobacillus brevis W63,
Lactobacillus casei W56, Lac-
tobacillus salivarius W24, Lactococcus
Total: 78
Placebo group: n=39
Intervention group:
n=39
5 × 109 cfu/day Placebo
 Intervention group: no difference in
endotoxin levels between groups;
significant improvement is shown in
WHR and HOMA-IR.
Frouzi et al
2017[24]
Malaysia
Randomized,
double-blind,
parallel-group,
con- trolled
clinical trial,
12 weeks
T2DM patients with established T2D
for at least 6 months prior to the
commencement of the study, not on
insulin and antibiotics, had glycated
hemoglobin A1c (HbA1c) between 6.5
and 12 %, had fasting blood glucose
(FBG) <15 mmol/L, had BMI between
18.5 and 40 kg/m2, and on a stabilized
dose of medication for at least 3
months before the study.
 Age: 30–70 y
Lactobacillus acidophilus,
Lactobacillus casei, Lactobacillus
lactis; Bifidobacte- rium bifidum,
Bifidobacterium longum and
Bifidobacterium infantis
Total: 136
Placebo group: n=68
Intervention group:
n=68
1 × 109 cfu/day
for each strain
Placebo
Intervention group: glycated
hemoglobin decreased by 0.14 % PP
analysis (p < 0.05, small effect size of
0.050), but not significant in ITT
analysis. Fasting insulin decreased by
2.9 μU/mL in probiotics group in PP
analysis, and was significant between
groups at both analyses (p < 0.05,
medium effect size of 0.062 in PP
analysis and small effect size of 0.033 in
ITT analysis)
(Continued on next page)
Study(year) Country
Study design
and duration Population, sex and age(y) Strain of probiotcis Sample size (n)
Probiotics
dose
Control
group
Results(Intervention vs control after
supplementation)
Sabico et al
2018[25]
the United
Kingdom
Randomized,
double-blind,
placebo-controlled
trial,
6 months
Adult Saudis with newly diagnosed
T2DM
Age: 30–60 y
Male: 40 (51.3%)
Female: 38 (48.7%)
Sachets with 2 g freeze-dried powder of
the probiotic mixture
®Ecologic®Barrier
(Winclove9probiotics, the
Netherlands).
Ecologic Barrier (2.5 × 109 cfu/g)
contains the following bacterial
strains: Bifidobacterium bifidum W23,
Bifi- dobacterium lactis W52,
Lactobacillus acidophilus W37,
Lactobacillus brevis W63,
Lactobacillus casei W56, Lac-
tobacillus salivarius W24, Lactococcus
lactis W19 and Lactococcus lactis W58.
Total: 78
Placebo group: n=39
Intervention group:
n=39
5 × 109 cfu/day Placebo
Intervention group: significant decreases
in circulating levels of endotoxin by
almost 70% over 6 months,  glucose
(38%), insulin (38%), HOMA-IR (64%),
triglycerides (48%), total cholesterol
(19%), total/HDL-cholesterol ratio (19%),
TNF-a (67%), IL-6 (77%), CRP (53%),
resistin (53%), and a significant increase
in adiponectin (72%) as compared with
baseline. Only HOMA-IR had a clinically
significant reduction (-3.4, 64.2%) in the
intervention group group as compared to
placebo group at all time points.
Raygan et al
2018[26] Iran
Randomized,
double-blind,
placebo-con-
trolled trial,
12 weeks
Patients with T2DM and 2- and 3-
vessel CHD
Age: 40–85 y
Bifidobacte- rium bifidum,
Lactobacillus casei, Lacto- bacillus
acidophilus
Total: 60
Placebo group: n=30
Intervention group:
n=30
2 × 109 cfu/day
for each strain Placebo
Intervention group: significantly
decreased fasting plasma glucose,
insulin, insulin resistance and total‐
/HDL‐cholesterol ratio, and significantly
increased insulin sensitivity and HDL‐
cholesterol levels compared with the
placebo.
Khalili et al
2018[27]
Iran
Parallel-group,
randomized
controlled trial,
8 weeks
Patients with T2DM
Male: 14 (35%)
Female: 26 (65%) L. casei
Total: 40
Placebo group: n=20
Intervention group:
n=20
108 cfu/day Placebo
Intervention group: significantly
decreased fasting blood sugar, insulin
concentration, and insulin resistance
compared with placebo group;
insignificant decrease of HbA1c.
Table 2 (continued)
Study(year) Country Study design and
duration
Population, sex and age(y) Strain of
probiotcis
Sample size (n) Probiotics dose Control
group
Results(Intervention vs control after
supplementation)
Tannaka et al
2015[28] Japan
Double-blind, parallel-
group comparison trial,
8 weeks
Female with mildly constipation
Age: 25-49 y
Bifidobacterium
animalis subsp.
lactis GCL2505 (B.
lactis GCL2505)
Total: 38
Placebo group: 20
Intervention
group: 18
100g test beveage/day Placebo
Intervention group: significantly increased
number of fecal bifidobacteria and the
frequency of defecation.
Mirghafourvand
et al 2016[29] Iran
Triple-blind
randomized controlled
trial,
4 weeks
Healthy singleton pregnant women
who suffered from constipation  Bifidobacterium,Lactobacillus
Total: 60
Placebo group: 30
Intervention
group: 30
4.8 × 1010 cfu/day Placebo
Intervention group: significantly increased
frequency of defecation; greatly improved
constipation symptoms including straining,
anorectal obstruction, manipulation to
facilitate defecation, consistency of stool and
color of stool.
Ding et al
2016[30]
China
Randomized, placebo-
controolled trial,
12 weeks
Adults with BMI 18.5–25 kg/m2 and
disgnosed chronic constipation,
complete bowel movements (SCBMs)
per week for a minimum of 6 months,
colonic transit time (CTT) >48 h,
mild-to-moderate constipation with a
Wexner constipation scale score
between 16 and 25
synbiotic
(BIFICOPEC) whih
contained 0.63 g of
bifid triple viable
capsules (BIFICO)
Total: 93
Placebo group: 45
Intervention
group: 48
two synbiotics
capsules/day Placebo
Intervention group: increased stool
frequency, stool consistency, decreased CTT,
and improved constipation-related symptoms.
Ibarra et al
2018[31] Finland
3-arm parallel-group
(alloca- tion ratio
1:1:1), double-blind,
randomized, placebo-
controlled, monocenter
trial,
28 days
Patients with BMI 18.5 to 34.9 kg/m2,
diagnosed with functional
constipation by the investigator per
the Rome III criteria in the last 3
months, with symptom onset
occurring at least 6 months prior to
the diagnosis
Age: 18-70 y
Bifidobacterium
animalis subsp.
lactis HN019
(HN019)
Total: 228
Placebo group: 76
Intervention group
(low dose): 76
Intercention group
(high dose): 76
Intervention group (low
dose): 109 cfu/day
Intercention group (high
dose): 1010 cfu/day
Placebo Intervention group: no statisticallysignificant differences.
(Continued on next page)
Table 3 Summary of RCTs about effect of probiotics on digestive health.
Study(year) Country Study design and
duration
Population, sex and age(y) Strain of
probiotcis
Sample size (n) Probiotics dose Control
group
Results(Intervention vs control after
supplementation)
Escribano et al
2018[32]
Spain
Multicenter, double‐
blind, randomized,
placebo‐controlled
parallel group trial,
12 weeks
Infants with normal birth weight (3rd
to 97th percentiles for gestational
age), normal growth curve according
to current Spanish references, and ≤3
months of age at enrolment
Age: ≤ 3 months
Male: 69 (45.7%)
Female: 82 (54.3%)
B. infantis IM1
Total: 151
Placebo group: 78
Intervention
group: 73
107 cfu/day Placebo
Intervention group: lower constipation
incidence, higher stool cnosistency and less
diarrhea episodes.
Yoon et al
2018[33]
Korea
Randomized, double-
blind, placebo-
controlled trial,
4 weeks
Patients with diagnosis of IBS-C or FC
(based on Rome IV criteria)
Age: 18-70 y
Male: 24 (14.0%)
Female: 147 (86.0%)
Streptococcus
thermophilus
MG510,
Lactobacillus
plantarum
LRCC5193
Total: 171
Placebo group: 83
Intervention
group: 88
3.0 × 108 cfu/day of
Streptococcus
thermophilus MG510
and 1.0 × 108 cfu/day of
Lactobacillus plantarum
LRCC5193
Placebo
Intervention group: significantly improved
stool consistency measured by the Bristol
Stool Form Scale (3.7 ± 1.1 vs. 3.1 ± 1.1 at 8
weeks, P = 0.002) and significantly bettter
quality of life ( at 8 weeks p = 0.049). No
significant difference was found in CSBM.
Gomi et al
2018[34] Japan
Double-blind,
randomized, placebo-
controlled trial,
4 weeks
Adults with temporary gastric
symptoms with a modified Frequency
Scale for Symptoms of Gastroesopha-
geal reflux disease (m-FSSG) score ≥8
but were not defined as having “
functional dyspepsia” by the Rome IV
classification
Age: 20-64 y
Male: 38 (48.1%)
Female: 41 (51.9%)
Bifidobacterium
bifidum YIT 10347
(YIT10347)
Total: 79
Placebo group: 40
Intervention
group: 39
Intervention group
YIT10347- 100 ml
fermented milk per day
which contained more
than 3 × 107 cfu/mL of
YIT10347 and more than
1 × 107 cfu/mL of S.
thermophilus YIT 2021.
Placebo groupe: 100 ml
placebo milk per day
which contained more
than 1 × 107 cfu/mL of S.
thermophilus YIT 2021
only.
Placebo
milk
Intervention group: higher relief rates of
overall gastrointestinal symptoms, upper
gastrointestinal symptoms, flatus, and
diarrhea.
(Continued on next page)
Table 3 (continued)
Study(year) Country Study design and
duration
Population, sex and age(y) Strain of
probiotcis
Sample size (n) Probiotics dose Control
group
Results(Intervention vs control after
supplementation)
Sun et al 2018[35] China
Multicenter,
randomized, double-
blind, placebo-
controlled trial,
4 weeks
Patients diagnosed with diarrhea-
predominant IBS (IBS-D)
Age: 18-65 y
Male: 116 (58%)
Female:84 (42%)
Clostridium
butyricum
Total: 200
Placebo group: 95
Intervention
group: 105
1.5 × 107/day Placebo
Intervention group: improved overall IBS-D
symptoms (−62.12 ± 74.00 vs. −40.74 ±
63.67, p=0.038) and quality of life (7.232 ±
14.06 vs. 3.159 ± 11.73, p=0.032) and stool
frequency (−1.602 ± 1.416 vs. −1.086 ± 1.644,
p=0.035).
Shin et al
2018[36]
Korea
Single center,
randomized, double-
blind and placebo-
controlled clinical
trial,
8 weeks
Subjects with diarrhea dominant IBS
according to the Rome III criteria
Age: 20–55 y
Male: 22 (43.1%)
Female:29 (56.9%)
Lactobacillus gasseri
BNR17
Total: 51
Placebo group: 27
Intervention
group: 24
1010 cfu/day Placebo
Intervention group: significantly
improvement of the symptoms of diarrhea,
abdominal pain, distension, disturbed daily
life, and mean defecation frequency.
Table 3 (continued)
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CONCLUSIONS 
 
Randomized clinical trials in recent three years have statistically suggested that intake of probiotics 
have a beneficial impact on obesity and T2DM, but not significant enough on digestive health. 
Considering the complexity of probiotics strains and consistency of data collected from these trials, 
more RCTs are necessarily needed to clarify the effect of probiotics in detail. 
Up to date, a great number of experiments or clinical trials on the effect of probiotics have provided 
evidence that probiotics can influence the composition of gut microbiota, and bring positive effect 
on human health. It is a promising therapeutic treatment for us. However, due to the complicated 
human body structure and difference among people's dietary routine, genetic background, and 
many other factors, probiotics may not have the same effect on everybody, and not all species of 
probiotics are good for us. All scientific and medical researchers agree that there is not enough 
evidence to reliably assess the possible role of probiotics in the treatment of all health disorders. 
In order to get more reliable results, further studies with a higher number of patients and animals 
should be done. Also, the specific assessment of probiotics function should also be clarified as a 
standard in all experiments.  
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